Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Ranolazine (Corzyna -- KYE pharmaceuticals Inc.) indication: patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies

The CADTH Canadian Drug Expert Committee (CDEC) recommends that ranolazine not be reimbursed as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium...

Full description

Bibliographic Details
Corporate Author: CADTH Canadian Drug Expert Committee
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health May 2021, 2021
Edition:Version: Final
Series:CADTH common drug review
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01330nam a2200229 u 4500
001 EB002138223
003 EBX01000000000000001276350
005 00000000000000.0
007 tu|||||||||||||||||||||
008 230103 r ||| eng
245 0 0 |a CADTH Canadian Drug Expert Committee recommendation: Ranolazine (Corzyna -- KYE pharmaceuticals Inc.)  |h Elektronische Ressource  |b indication: patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies 
246 3 1 |a Ranolazine (Corzyna -- KYE pharmaceuticals Inc.) 
250 |a Version: Final 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c May 2021, 2021 
300 |a 1 PDF file (7 pages) 
710 2 |a CADTH Canadian Drug Expert Committee 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH common drug review 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK583807  |3 Volltext 
082 0 |a 610 
520 |a The CADTH Canadian Drug Expert Committee (CDEC) recommends that ranolazine not be reimbursed as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers 

Similar Items